The visit note, written while you talk and ready for your signature

With the patient's consent Mosaic listens, reads what you open on screen, and writes the note in the structure your practice uses. You read it, change what you want and sign.

Step 1

AKAnna Keller, 47 · Hypertension, prediabetes, LDL 162 mg/dl · 14 documents, read 16 September 2026

Given her history and today's findings, what should I consider next?

Answered on 16 September 2026

Finished thinking

Practice guidelineEuropean Society of Cardiology

ESC 2021: in apparently healthy people under 50, SCORE2 estimates the 10-year risk; risk modifiers such as a family history of premature cardiovascular disease, lipoprotein(a) and coronary artery calcium can move a patient across a treatment threshold. At low-to-moderate risk, lipid-lowering treatment should be considered when LDL cholesterol stays at or above 100 mg/dl after lifestyle intervention. Eur Heart J

European Society of Cardiology

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice.

Visseren FLJ, Mach F, Smulders YM, et al. European Heart Journal. 2021;42:3227-3337. doi:10.1093/eurheartj/ehab484.

Her SCORE2 (moderate-risk region, 47 years, non-smoker now, systolic 142, non-HDL 186 mg/dl) is about 3 %, low to moderate for her age. Check-up 12.05.2026 Lab 08.05.2026 Eur Heart J Three modifiers push upward: her father's infarction at 58, an LDL of 162 mg/dl and prediabetes with steatosis. Intake 20.09.2023 Lab 08.05.2026 Ultrasound 12.05.2026

Lipids: statin rechallenge with atorvastatin 10 mg or rosuvastatin 5 mg, LDL target below 100 mg/dl, lipids, ALT and CK after eight weeks; lipoprotein(a) once with the next draw. Eur Heart J + 2
Blood pressure: home mean 136/86 is above the ESC 2024 target of 120 to 129 systolic; increase ramipril to 10 mg, potassium and creatinine after two weeks, home log again in four weeks. BP log 15.09.2026 Eur Heart J
Prediabetes and liver: structured lifestyle programme (the Diabetes Prevention Program reduced diabetes incidence by 58 %), HbA1c in three to six months, FIB-4 from the May values. NEJM J Hepatol
Optional risk refinement: a coronary calcium scan if she or you want more certainty before committing to long-term treatment. Eur Heart J

Today's draft note already lists the statin start, the ramipril increase and the booster; the FIB-4 and the lifestyle programme are not yet in it. Visit 16.09.2026

See the full response

Step 2

AKAnna Keller, 47 · Hypertension, prediabetes, LDL 162 mg/dl

Write the note from today's visit.

Finished thinking

Drafted in the practice's structure, for your signature

Visit note

Visit of 16 September 2026

Anna Keller, 47 · 16 September 2026 · Signed, in the chart

Reason: Blood pressure control, lipids, decision on statin therapy.
Findings: BP 142/88, HR 72, BMI 29.1. Lab 12 September: LDL 162 mg/dl, HbA1c 5.9 %, ALT 41 U/l. Father: myocardial infarction at 58. Simvastatin stopped 2024 for myalgia.
Assessment: Hypertension not at target under ramipril 5 mg; primary prevention with high LDL and premature family history; prediabetes; mild steatosis.
Plan: Atorvastatin 20 mg started, CK and ALT after six weeks; lipoprotein(a) once; ramipril to 10 mg; home blood pressure for four weeks; follow-up in three months.

Written from the recording of the visit and what was open on screen, in the practice's structure. Signed by Dr. med. Sarah Weber; every sentence points to its passage in the conversation.

Open the visit note See the full response

Step 3

AKAnna Keller, 47 · Hypertension, prediabetes, LDL 162 mg/dl · 14 documents, read 16 September 2026

Does atorvastatin interact with her current medication?

Answered on 16 September 2026

Finished thinking

Her current medication: ramipril 5 mg, sertraline 50 mg. Medication 16.09.2026 No clinically relevant interaction with either. Atorvastatin is metabolised by CYP3A4; the interactions that matter are with strong CYP3A4 inhibitors such as clarithromycin, itraconazole and ritonavir, with ciclosporin and gemfibrozil, and with large amounts of grapefruit juice. None is on her list. Eur Heart J

The relevant safety question is the earlier myalgia, not an interaction: start low (10 mg), take it in the evening, document the baseline CK (96 U/l in May) and re-check CK and ALT at eight weeks or earlier if symptoms return. Lab 08.05.2026 Visit 14.03.2024 Eur Heart J If a macrolide is ever prescribed for an infection, pause atorvastatin for the course. Eur Heart J

See the full response